Anders Research
Subscribe
Sign in
Home
Archive
About
Latest
Top
Discussions
INmune Bio: Imminent Phase 2 Alzheimer's Readout of Unique Asset Presents Interesting Speculative Opportunity
Strong preclinical, supporting, and early clinical data make INmune Bio's Phase 2 readout of XPro1595 in Alzheimer's disease a high risk/reward…
Jun 16
•
Anders Research
1
Share this post
Anders Research
INmune Bio: Imminent Phase 2 Alzheimer's Readout of Unique Asset Presents Interesting Speculative Opportunity
Copy link
Facebook
Email
Notes
More
8
May 2025
Alpha Cognition: Launching Well-Differentiated Drug into a large Alzheimer's Market Opportunity
**NOTE: Smaller updates and positioning are posted to X/Twitter**
May 13
•
Anders Research
3
Share this post
Anders Research
Alpha Cognition: Launching Well-Differentiated Drug into a large Alzheimer's Market Opportunity
Copy link
Facebook
Email
Notes
More
2
April 2024
Annovis: Imminent Alzheimer's Data Difficult to Handicap; Optimistic Overall
Given our optimistic view on Phase 3 Parkinson's data, we are inclined to expect some positive signs in Alzheimer's.
Apr 29, 2024
•
Anders Research
6
Share this post
Anders Research
Annovis: Imminent Alzheimer's Data Difficult to Handicap; Optimistic Overall
Copy link
Facebook
Email
Notes
More
March 2024
Aquestive Therapeutics (AQST): Underappreciated Late-Stage Assets Present Significant Long-Term Opportunity Despite Recent Gains
Sublingual form of EpiPen presents a paradigm shift for patients; potential to capture share and expand overall market size.
Mar 17, 2024
•
Anders Research
2
Share this post
Anders Research
Aquestive Therapeutics (AQST): Underappreciated Late-Stage Assets Present Significant Long-Term Opportunity Despite Recent Gains
Copy link
Facebook
Email
Notes
More
February 2024
Annovis: Potentially Encouraging Patient Anecdotes and Weighing Phase 3 Parkinson’s Prospects
Inherently risky, but patient anecdotes and totality of evidence suggest underlying activity in Parkinson's disease.
Feb 12, 2024
•
Anders Research
1
Share this post
Anders Research
Annovis: Potentially Encouraging Patient Anecdotes and Weighing Phase 3 Parkinson’s Prospects
Copy link
Facebook
Email
Notes
More
January 2024
MAIA Biotechnology: Significantly Undervalued with Novel Mechanism and Impressive Early Data
Asymmetric high-risk/high-reward; worthy of at least a speculative position.
Jan 5, 2024
•
Anders Research
1
Share this post
Anders Research
MAIA Biotechnology: Significantly Undervalued with Novel Mechanism and Impressive Early Data
Copy link
Facebook
Email
Notes
More
November 2023
BioVie: Cautiously Optimistic Ahead of Phase 3 Alzheimer’s Data Unblinding
Worth watching/speculative position; no price target.
Nov 21, 2023
•
Anders Research
4
Share this post
Anders Research
BioVie: Cautiously Optimistic Ahead of Phase 3 Alzheimer’s Data Unblinding
Copy link
Facebook
Email
Notes
More
2
October 2023
Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024
~10x Potential Over the Next 12-24 months
Oct 17, 2023
•
Anders Research
Share this post
Anders Research
Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024
Copy link
Facebook
Email
Notes
More
1
September 2023
Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum
2024 Price Target: $13.96 (+422%)
Sep 19, 2023
•
Anders Research
1
Share this post
Anders Research
Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum
Copy link
Facebook
Email
Notes
More
April 2023
Annovis: Making Sense of the Interim Analysis
Recent PR missteps were inadvertent; reiterate 12-month price target: $107/share
Apr 11, 2023
•
Anders Research
Share this post
Anders Research
Annovis: Making Sense of the Interim Analysis
Copy link
Facebook
Email
Notes
More
March 2023
Annovis and Buntanetap: Asymmetric Risk/Reward Ahead of Interim Phase 3 Parkinson’s Data Readout
12-Month Price Target: $117/share (+430%)
Mar 30, 2023
•
Anders Research
Share this post
Anders Research
Annovis and Buntanetap: Asymmetric Risk/Reward Ahead of Interim Phase 3 Parkinson’s Data Readout
Copy link
Facebook
Email
Notes
More
4
July 2022
Axsome: One Step At A Time
Maintain 24-Month Price Target: $150/share (+270%)
Jul 1, 2022
•
Anders Research
1
Share this post
Anders Research
Axsome: One Step At A Time
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
